Turning Point Therapeutics, Inc. Net Income
Turning Point Therapeutics, Inc. reported Net Income of -$123.09 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Income Statement
us-gaap:NetIncomeLoss · last filed 2022-08-08
- Turning Point Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2022-06-30 was -$123.09M.
- Turning Point Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2022-03-31 was -$74.44M.
- Turning Point Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2021-12-31 was -$78.45M.
- Turning Point Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2021-09-30 was -$66.33M.
- Turning Point Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2021 was -$236.55M.
- Turning Point Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2020 was -$157.29M.
- Turning Point Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2019 was -$72.13M.
- Turning Point Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2018 was -$24.79M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$123.09M 10-Q · filed 2022-08-08 | -$197.53M 10-Q · filed 2022-08-08 | -$275.98M derived: sum of 3 quarters · filed 2022-08-08 | -$342.31M derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | -$74.44M 10-Q · filed 2022-08-08 | -$152.89M derived: sum of 2 quarters · filed 2022-08-08 | -$219.22M derived: sum of 3 quarters · filed 2022-08-08 | -$275.49M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-12-31 | -$78.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$144.77M derived: sum of 2 quarters · filed 2022-02-28 | -$201.05M derived: sum of 3 quarters · filed 2022-08-08 | -$236.55M 10-K · filed 2022-02-28 |
| 2021-09-30 | -$66.33M 10-Q · filed 2021-11-09 | -$122.60M derived: sum of 2 quarters · filed 2022-08-08 | -$158.10M 10-Q · filed 2021-11-09 | -$205.48M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-06-30 | -$56.27M 10-Q · filed 2022-08-08 | -$91.78M 10-Q · filed 2022-08-08 | -$139.15M derived: sum of 3 quarters · filed 2022-08-08 | -$156.86M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$35.50M 10-Q · filed 2022-08-08 | -$82.88M derived: sum of 2 quarters · filed 2022-08-08 | -$100.58M derived: sum of 3 quarters · filed 2022-08-08 | -$132.08M derived: sum of 4 quarters · filed 2022-08-08 |
| 2020-12-31 | -$47.38M 10-K · filed 2021-03-01 | -$65.08M derived: sum of 2 quarters · filed 2021-11-09 | -$96.57M derived: sum of 3 quarters · filed 2021-11-09 | -$157.29M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$17.70M 10-Q · filed 2021-11-09 | -$49.20M derived: sum of 2 quarters · filed 2021-11-09 | -$109.92M 10-Q · filed 2021-11-09 | -$130.88M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$31.49M 10-Q · filed 2021-11-09 | -$92.21M 10-Q · filed 2021-08-09 | -$113.17M derived: sum of 3 quarters · filed 2021-11-09 | -$133.65M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-03-31 | -$60.72M 10-Q · filed 2021-11-09 | -$81.68M derived: sum of 2 quarters · filed 2021-11-09 | -$102.16M derived: sum of 3 quarters · filed 2021-11-09 | -$119.30M derived: sum of 4 quarters · filed 2021-11-09 |
| 2019-12-31 | -$20.96M 10-K · filed 2021-03-01 | -$41.44M derived: sum of 2 quarters · filed 2021-03-01 | -$58.58M derived: sum of 3 quarters · filed 2021-03-01 | -$72.13M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$20.48M 10-K · filed 2021-03-01 | -$37.63M derived: sum of 2 quarters · filed 2021-03-01 | -$51.17M 10-Q · filed 2020-11-12 | -$60.19M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$17.14M 10-K · filed 2021-03-01 | -$30.69M 10-Q · filed 2020-08-10 | -$39.71M derived: sum of 3 quarters · filed 2021-03-01 | -$45.70M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$13.55M 10-K · filed 2021-03-01 | -$22.57M derived: sum of 2 quarters · filed 2021-03-01 | -$28.56M derived: sum of 3 quarters · filed 2021-03-01 | -$33.60M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$9.02M 10-K · filed 2020-03-18 | -$15.02M derived: sum of 2 quarters · filed 2020-03-18 | -$20.05M derived: sum of 3 quarters · filed 2020-03-18 | -$24.79M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$6.00M 10-K · filed 2020-03-18 | -$11.03M derived: sum of 2 quarters · filed 2020-03-18 | -$15.77M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | -$5.04M 10-K · filed 2020-03-18 | -$9.77M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | -$4.73M 10-K · filed 2020-03-18 | |||
| 2017-12-31 | -$16.59M 10-K · filed 2020-03-18 |